A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome

Trial Profile

A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 24 Nov 2017

At a glance

  • Drugs Bardoxolone methyl (Primary)
  • Indications Hereditary nephritis
  • Focus Registrational; Therapeutic Use
  • Acronyms CARDINAL
  • Sponsors Reata Pharmaceuticals
  • Most Recent Events

    • 03 Nov 2017 Results from the phase II portion of this trial published in a Reata Pharmaceuticals media release.
    • 03 Nov 2017 According to a Reata Pharmaceuticals media release, results from the phase II portion of this trial were presented at the American Society of Nephrology Kidney Week 2017 Annual Meeting.
    • 03 Nov 2017 Primary endpoint of the phase II portion (Increase in eGFR from baseline at 12 weeks) has been met, according to a Reata Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top